Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials
Silvio Danese(IRCCS Ospedale San Raffaele), Séverine Vermeire(KU Leuven), Wen Zhou(AbbVie (United States)), Aileen L. Pangan(AbbVie (United States)), Jesse Siffledeen(University of Alberta), Susan Greenbloom, Xavier Hébuterne(Université Côte d'Azur), Geert D’Haens(Amsterdam University Medical Centers), Hiroshi Nakase(Sapporo Medical University), Julián Panés(Hospital Clínic de Barcelona), Peter Higgins(University of Michigan), Pascal Juillerat(University Hospital of Bern), James O. Lindsay(Queen Mary University of London), Edward V. Loftus(Mayo Clinic in Arizona), William J. Sandborn(University of California San Diego), Walter Reinisch(Medical University of Vienna), Minhu Chen(Sun Yat-sen University), Yuri Sánchez González(AbbVie (United States)), Bidan Huang(AbbVie (United States)), Wangang Xie(AbbVie (United States)), John Liu(AbbVie (United States)), Michael Weinreich(AbbVie (United States)), Remo Panaccione(University of Calgary)
Cited by 583Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis